UK companies advance development of regenerative medicines and cell therapies

The results of the 2015 Innovate UK competition in Developing Regenerative Medicines and Cell Therapies are now online:

Go to the profile of Magda Papadaki
Feb 01, 2016

Regenerative medicines and cell therapies hold unprecedented promise to treat many areas of unmet medical need and chronic burden. Turning these promising discoveries into products, services and sustainable businesses is crucial if the UK is to become a global leader in the field, calling for truly innovative thinking and strong interdisciplinary collaboration.

Innovate UK looks for innovative regenerative medicine, cell and gene therapy projects

Since 2009, Innovate UK’s Regenerative Medicine programme has been building on the country’s strengths, including its world-leading research base and centralized health system, to support the development and commercialization of Regenerative Medicines and Cell Therapies, as well as underpinning tools and technologies. To date the program has funded 87 feasibility or collaborative R&D projects focused on the engineering, manufacture, distribution and supply of potential new treatments for a variety of health challenges such as arthritis, cancer, diabetes, stroke, and wound healing, as well as less common “orphan” indications where there is currently no treatment.

With our 2015 competition ‘Developing Regenerative Medicines and Cell Therapies’, Innovate UK looked to invest up to £8 million in collaborative R&D projects that address critical challenges faced by UK companies developing regenerative medicines and cell therapies as clinical treatments and commercial products.

Five exciting projects win funding

The five collaborative projects that succeeded in the final assessment of the competition are led by Cobra Biologics Ltd, Synpromics Ltd, ReNeuron Limited and Autolus Ltd.Their collaborators span across the academic, research and industry communities, including Touchlight Genetics Ltd, University College London, Cell Therapy Catapult and Centre for Process Innovation.

The full details on this year's competition and the successful applicants can be found online:

Go to the profile of Magda Papadaki

Magda Papadaki

Lead Technologist, Regenerative Medicine & Cell Therapies, Innovate UK

Lead Technologist for Innovate UK's program in Regenerative Medicine and Cell Therapies. The program aims to grow the UK’s enterprise in advanced treatments, identifying and funding promising discoveries alongside solutions in process and business that can advance the entire path to market and clinical adoption. A stem cell/ gene therapy scientist by training, combines over a decade in academic research, with regulatory and business experience in the EU and US. She is an expert in the development of adaptive pathways and stakeholder partnerships to reshape the development and commercialization of ATMPs. Before joining Innovate UK, she was a member of the global consortium developing the Adaptive Licensing paradigm and has worked extensively in the global space of public-private partnerships, including the EU Innovative Medicines Initiative and the US/FDA C-Path initiative. Her experience in the pharma industry has been with Novartis, leading the Regulatory Affairs functions for Consumer Health in Greece and Cyprus.

No comments yet.